Imatinib Completed Phase 2 Trials for Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00237185A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene